CFO
ATNM icon

Callan Family Office’s Actinium Pharmaceuticals ATNM Stock Holding History

Callan Family Office’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9K Sell
11,944
-11,659
-49% -$13.9K ﹤0.01% 1130
2025
Q4 		$32.1K Hold
23,603
– – ﹤0.01% 1101
2025
Q3 		$37.8K Hold
23,603
– – ﹤0.01% 837
2025
Q2 		$33K Hold
23,603
– – ﹤0.01% 904
2025
Q1 		$38K Buy
+23,603
New +$30K ﹤0.01% 541

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Callan Family Office's ATNM Position: Q1 2026 in Review

Callan Family Office reduced its Actinium Pharmaceuticals (ATNM) stake by 49% in Q1 2026, selling an estimated $13.9K and leaving 11,944 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1130.

Callan Family Office first reported a position in ATNM in Q1 2025 and has held it in 5 quarters since. The position peaked at $38K in Q1 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Callan Family Office held 11,944 shares of Actinium Pharmaceuticals worth $11.9K as of Q1 2026.
  • Callan Family Office sold 11,659 Actinium Pharmaceuticals shares in Q1 2026, an estimated $13.9K.
  • Actinium Pharmaceuticals made up ﹤0.01% of Callan Family Office's portfolio in Q1 2026, its #1130 holding.
  • Callan Family Office first reported a position in Actinium Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Callan Family Office's Actinium Pharmaceuticals position peaked at $38K in Q1 2025.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.